After hosting a call with a physician who has "deep expertise" in movement disorders and is familiar with the use of VMAT2 inhibitors in various hyperkinetic disorders, having treated thousands of pediatric Tourette's Syndrome patients, Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Neurocrine Biosciences with a $150 price target. The physician noted that current approved treatments in Tourette's Syndrome, haloperidol, pimozide, and aripiprazole come with "many unwanted side effects that clearly overshadow any efficacy benefits," Duncan tells investors in a research note. The doctor he spoke to almost never uses these drugs in his pediatric Tourette's Syndrome patients, instead preferring off-label medications. Duncan says he now has increased conviction in not only the probability of Neurocrine's TForce Gold trial success, but also in the market opportunity for valbenazine in Tourette's Syndrome. He reiterates an Overweight rating on the shares with a $150 price target.